Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioVeris Corp.

Division of Roche
www.bioveris.com

Latest From BioVeris Corp.

Roche Pounces On Market-Weakened Illumina

Roche’s $5.7 billion hostile takeover offer for Illumina is opportunistic as well as strategic. It is a validation of Illumina’s long-term growth potential but also takes advantage of a depressed stock price due to the global economic slowdown and cutbacks in government funding that have hurt Illumina and other providers of gene sequencing instrumentation.

Medical Device BioPharmaceutical

Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q2 2007

In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for April-June 2007. Our data are derived from Windhover's Strategic Transactions Database.
BioPharmaceutical Medical Device

In Vitro Diagnostics: Innovation and Integration

Integration is occuring at almost every level of the in vitro diagnostic industry--at the preclinical level to decrease drug development costs and timelines and at the clinical level to better manage diseases. In the lab, there's a demand for new tools to improve speed and efficiency, and new information systems to better integrate disparate data. At the same time, there has been a flurry of integration and consolidation at the market level, with 35 mergers and acquisitions in the last 12 months.
Medical Device

Does Roche Have It Right?

Roche's hostile tender offer for Ventana Medical Systems, and to a lesser extent its recent acquisitions of life science tools companies this year, highlight the firm's belief in diagnostics and its bet that personalized medicine--an area where innovative platforms and molecular test content will play significant if separate roles--will be key to its long-term growth. It could be an expensive and risky strategy that will take years to come to fruition.
Medical Device Business Strategies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
    • Vaccines
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • Samuel Wohlstadter, Chmn. & CEO
    Charles Migausky, VP, CFO
  • Contact Info
  • BioVeris Corp.
    Phone: (800) 336-4436
    16020 Industrial Dr.
    Gaithersburg, MD 20877
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register